XIIDRA
(lifitegrast ophthalmic solution)

RATIONALE FOR INCLUSION IN PA PROGRAM

Background
Xiidra ophthalmic solution is used to treat dry eye disease. Xiidra contains lifitegrast ophthalmic solution packaged in sterile, preservative-free single-use vials and is administered every 12 hours. Dry eye disease includes a group of conditions in which the eye does not produce an adequate volume of tears or when the tears are not of the correct consistency. In patients whose tear production is presumed to be suppressed due to ocular inflammation due to dry eye disease, lifitegrast solution increases tear production and is thought to act as a partial immunomodulator (1-2).

Regulatory Status
FDA-approved indication: Xiidra is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the treatment of the signs and symptoms of dry eye disease (DED) (1).

The safety and efficacy of Xiidra has not been established in pediatric patients below the age of 17 (1).

Summary
Xiidra ophthalmic solution is used to treat chronic dry. Dry eye disease includes a group of conditions in which the eye does not produce an adequate volume of tears or when the tears are not of the correct consistency. In patients whose tear production is presumed to be suppressed due to ocular inflammation due to dry eye disease, lifitegrast solution increases tear production and is thought to act as a partial immunomodulator. The safety and efficacy of Xiidra ophthalmic solution have not been established in pediatric patients below the age of 17 (1-2).

Prior approval is required to ensure the safe, clinically appropriate and cost effective use of Xiidra while maintaining optimal therapeutic outcomes.

References